2017 Q1 Form 10-Q Financial Statement
#000143774917008297 Filed on May 08, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $4.900M | $5.300M |
| YoY Change | -7.55% | -10.17% |
| Cost Of Revenue | $10.50M | |
| YoY Change | 118.75% | |
| Gross Profit | -$5.200M | |
| YoY Change | -572.73% | |
| Gross Profit Margin | -98.11% | |
| Selling, General & Admin | $1.800M | $2.300M |
| YoY Change | -21.74% | -28.13% |
| % of Gross Profit | ||
| Research & Development | $6.800M | $8.500M |
| YoY Change | -20.0% | 77.08% |
| % of Gross Profit | ||
| Depreciation & Amortization | $100.0K | $0.00 |
| YoY Change | -100.0% | |
| % of Gross Profit | ||
| Operating Expenses | $6.800M | $8.500M |
| YoY Change | -20.0% | 77.08% |
| Operating Profit | -$3.800M | -$5.200M |
| YoY Change | -26.92% | -572.73% |
| Interest Expense | $100.0K | |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | -$400.0K | |
| YoY Change | ||
| Pretax Income | -$4.200M | -$5.200M |
| YoY Change | -19.23% | -533.33% |
| Income Tax | $200.0K | |
| % Of Pretax Income | ||
| Net Earnings | -$4.400M | -$5.200M |
| YoY Change | -15.38% | -533.33% |
| Net Earnings / Revenue | -89.8% | -98.11% |
| Basic Earnings Per Share | -$0.11 | -$0.14 |
| Diluted Earnings Per Share | -$0.11 | -$0.14 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 38.65M | 38.64M |
| Diluted Shares Outstanding | 38.65M | 38.64M |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $37.60M | $49.00M |
| YoY Change | -23.27% | -33.33% |
| Cash & Equivalents | $11.80M | $30.60M |
| Short-Term Investments | $25.80M | $18.40M |
| Other Short-Term Assets | $2.200M | $1.400M |
| YoY Change | 57.14% | 55.56% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $6.600M | $10.10M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $46.40M | $60.50M |
| YoY Change | -23.31% | -30.78% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $300.0K | $400.0K |
| YoY Change | -25.0% | 33.33% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $1.000M | |
| YoY Change | 11.11% | |
| Other Assets | $0.00 | |
| YoY Change | -100.0% | |
| Total Long-Term Assets | $300.0K | $1.400M |
| YoY Change | -78.57% | 0.0% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $46.40M | $60.50M |
| Total Long-Term Assets | $300.0K | $1.400M |
| Total Assets | $46.70M | $61.90M |
| YoY Change | -24.56% | -30.29% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.800M | $3.700M |
| YoY Change | -51.35% | 270.0% |
| Accrued Expenses | $3.000M | $4.500M |
| YoY Change | -33.33% | 0.0% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $300.0K | $500.0K |
| YoY Change | -40.0% | |
| Total Short-Term Liabilities | $5.500M | $8.700M |
| YoY Change | -36.78% | 20.83% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $100.0K | $300.0K |
| YoY Change | -66.67% | |
| Other Long-Term Liabilities | $200.0K | $200.0K |
| YoY Change | 0.0% | 100.0% |
| Total Long-Term Liabilities | $200.0K | $200.0K |
| YoY Change | 0.0% | 100.0% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $5.500M | $8.700M |
| Total Long-Term Liabilities | $200.0K | $200.0K |
| Total Liabilities | $22.50M | $9.200M |
| YoY Change | 144.57% | 26.03% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$157.8M | -$127.3M |
| YoY Change | 23.96% | 43.03% |
| Common Stock | $163.0M | $161.1M |
| YoY Change | 1.18% | 6.34% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $24.20M | $52.70M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $46.70M | $61.90M |
| YoY Change | -24.56% | -30.29% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$4.400M | -$5.200M |
| YoY Change | -15.38% | -533.33% |
| Depreciation, Depletion And Amortization | $100.0K | $0.00 |
| YoY Change | -100.0% | |
| Cash From Operating Activities | -$11.50M | -$7.000M |
| YoY Change | 64.29% | -975.0% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | -$100.0K |
| YoY Change | -100.0% | 0.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$14.70M | -$1.200M |
| YoY Change | 1125.0% | -400.0% |
| Cash From Investing Activities | -$14.70M | -$1.300M |
| YoY Change | 1030.77% | -533.33% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -100.0K | -100.0K |
| YoY Change | 0.0% | |
| NET CHANGE | ||
| Cash From Operating Activities | -11.50M | -7.000M |
| Cash From Investing Activities | -14.70M | -1.300M |
| Cash From Financing Activities | -100.0K | -100.0K |
| Net Change In Cash | -26.30M | -8.400M |
| YoY Change | 213.1% | -863.64% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$11.50M | -$7.000M |
| Capital Expenditures | $0.00 | -$100.0K |
| Free Cash Flow | -$11.50M | -$6.900M |
| YoY Change | 66.67% | -866.67% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | avir |
Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
|
2200000 | |
| CY2016Q2 | avir |
Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
|
2200000 | |
| avir |
Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
|
P1Y | ||
| CY2017Q1 | avir |
Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
|
500000 | |
| CY2016Q1 | avir |
Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
|
||
| avir |
Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
|
1400000 | ||
| avir |
Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
|
|||
| CY2017Q1 | avir |
Noncash Royalty Revenue Related To Sale Of Future Royalties
NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
800000 | |
| CY2016Q1 | avir |
Noncash Royalty Revenue Related To Sale Of Future Royalties
NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
||
| avir |
Noncash Royalty Revenue Related To Sale Of Future Royalties
NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
3000000 | ||
| avir |
Noncash Royalty Revenue Related To Sale Of Future Royalties
NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
|
|||
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1800000 | |
| CY2016Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3900000 | |
| CY2017Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6600000 | |
| CY2016Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
700000 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3000000 | |
| CY2016Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3600000 | |
| CY2017Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
400000 | |
| CY2016Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
100000 | |
| CY2017Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
19000000 | |
| CY2016Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
19000000 | |
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
159100000 | |
| CY2016Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
157600000 | |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1500000 | ||
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
500000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
500000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1400000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1600000 | ||
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6635527 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4639959 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6635527 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4639959 | ||
| CY2017Q1 | us-gaap |
Assets
Assets
|
46700000 | |
| CY2016Q2 | us-gaap |
Assets
Assets
|
72700000 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
46400000 | |
| CY2016Q2 | us-gaap |
Assets Current
AssetsCurrent
|
72400000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
33200000 | |
| CY2016Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
20800000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
||
| CY2016Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
100000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
||
| CY2016Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
||
| CY2017Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
33200000 | |
| CY2016Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
20700000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
33200000 | |
| CY2016Q2 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
20800000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11800000 | |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49700000 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-100000 | |
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
44700000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30600000 | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-37900000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-14100000 | ||
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.10 | |
| CY2016Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.10 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38649237 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38640487 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38649237 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38640487 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
3900000 | |
| CY2016Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
3900000 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
400000 | |
| CY2016Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1300000 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
16700000 | |
| CY2016Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
16800000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.11 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.14 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.61 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.48 | ||
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.11 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.14 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.61 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.48 | ||
| CY2017Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.11 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.14 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.61 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.48 | ||
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
400000 | |
| CY2016Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
600000 | |
| CY2016Q3 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
| CY2015Q3 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
| CY2016Q4 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
| CY2015Q4 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2400000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y219D | ||
| CY2016Q3 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2015Q3 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2016Q4 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2015Q4 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2017Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
300000 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
300000 | |
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-100000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-200000 | ||
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1800000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2300000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6000000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6700000 | ||
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4200000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5200000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-23200000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-18400000 | ||
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
200000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
300000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
|||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2800000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-100000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5200000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2500000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-500000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
800000 | ||
| CY2017Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
100000 | |
| CY2016Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
100000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
100000 | ||
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
22500000 | |
| CY2016Q2 | us-gaap |
Liabilities
Liabilities
|
26500000 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
46700000 | |
| CY2016Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
72700000 | |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5500000 | |
| CY2016Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9200000 | |
| CY2017Q1 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
100000 | |
| CY2016Q2 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
300000 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1)</div> </div> <div style="display: inline; font-weight: bold;">Company Overview</div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BTA585</div> (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BTA074,</div> an antiviral treatment for condyloma caused by human papillomavirus types <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> & <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">We also have preclinical RSV non-fusion inhibitor program that we believe complements our F-protein inhibitor <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BTA585.</div> The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Although several of the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not successfully derive any significant product revenues from any product candidates that it is developing now, or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company announced that it plans to explore a wide range of strategic alternatives that include a business combination or strategic merger, in-licensing clinical stage programs, an acquisition, or other transaction that would complement the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s current pipeline and could maximize both near and long-term value for its shareholders. The Company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process. During the strategic alternatives process, the Company plans to continue to finance its operations with its existing cash. The Company’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources (including royalty revenue received under existing licenses) as it continues with its ongoing clinical development activities. Aviragen does not have a defined timeline for the exploration of strategic alternatives there can be no assurance that the process will result in any strategic alternative being announced or consummated. Aviragen does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate.</div></div></div> | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-200000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-200000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-6500000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
1300000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-31200000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-15200000 | ||
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4400000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5200000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-23500000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-18400000 | ||
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-400000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1300000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
100000 | ||
| CY2016Q2 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
400000 | |
| CY2017Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
8700000 | |
| CY2016Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
10500000 | |
| us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
30700000 | ||
| us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
27300000 | ||
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3800000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5200000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21900000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18500000 | ||
| CY2017Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
||
| CY2016Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
700000 | |
| CY2017Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
200000 | |
| CY2016Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
200000 | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
26800000 | ||
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
13500000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
|||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
100000 | ||
| CY2017Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.10 | |
| CY2016Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.10 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2200000 | |
| CY2016Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2700000 | |
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
20300000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
14900000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | ||
| CY2017Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
300000 | |
| CY2016Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
300000 | |
| us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
200000 | ||
| us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
200000 | ||
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6800000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8500000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24600000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20400000 | ||
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-157800000 | |
| CY2016Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-134300000 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
4900000 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
5300000 | |
| us-gaap |
Revenues
Revenues
|
8800000 | ||
| us-gaap |
Revenues
Revenues
|
8800000 | ||
| CY2017Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
4100000 | |
| CY2016Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
5300000 | |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
5800000 | ||
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
8800000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1400000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1600000 | ||
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
||
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
|||
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0127 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.011 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0119 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.015 | ||
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.0065 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.0076 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.0071 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.0075 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
170703 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
337193 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2392000 | ||
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.24 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.88 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.58 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.34 | ||
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4751423 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6635527 | |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.07 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.05 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
|||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
4.46 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
2.35 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.02 | ||
| CY2017Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
2687143 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
6635527 | |
| CY2017Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P2Y | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y73D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y182D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y182D | ||
| CY2017Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
5.27 | |
| CY2017Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
3.05 | |
| us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y182D | ||
| CY2017Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
25800000 | |
| CY2016Q2 | us-gaap |
Short Term Investments
ShortTermInvestments
|
19300000 | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
|||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
|||
| CY2016Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
46200000 | |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24200000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
38647487 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
38640254 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
38642786 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
38633786 | ||
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38647487 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38640254 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38642786 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38633786 | ||
| CY2017Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38647487 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38640254 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38642786 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
38633786 |
